FDA approves new drug for binge eating disorder (BED)

2 febrero 2015

The United States Food and Drug Administration (FDA) recently approved lisdexamfetamine dimesylate, under the brand name Vyvanse, to treat moderate to severe binge eating disorder (BED) in adults, a first of its kind prescription drug specifically indicated for BED. Experts say that understanding the differences between obesity and BED is important for clinicians, as BED is an eating disorder that affects only a portion of those with the medical disease obesity.